Cost-effectiveness of using adjunctive porcine small intestine submucosa trilayer matrix compared with standard care in managing diabetic foot ulcers in the US

J. F. Guest, D. Weidlich, H. Singh, J. La Fontaine, A. Garrett, C. J. Abularrage, C. R. Waycaster

Research output: Contribution to journalArticle

Abstract

Objective: To estimate the cost-effectiveness of using tri-layer porcine small intestine submucosa (SIS; Oasis Ultra) as an adjunct to standard care compared with standard care alone in managing diabetic foot ulcers (DFUs) in the US, from the perspective of Medicare. Method: A Markov model was constructed to simulate the management of diabetic neuropathic lower extremity ulcers over a period of one year in the US. The model was used to estimate the costeffectiveness of initially using adjunctive SIS compared with standard care alone to treat a DFU in the US at 2016 prices. Results: At 12 months after the start of treatment, the use of adjunctive SIS instead of standard care alone is expected to lead to a 42 % increase in the number of ulcer-free months, 32 % increase in the probability of healing, a 3 % decrease in the probability of developing complicated ulcers and a 1 % decrease in the probability of undergoing an amputation. Health-care resource use is expected to be reduced by 11-14 % among patients who are initially managed with adjunctive SIS compared with those initially managed with standard care alone, with the exception of debridement, which is expected to be reduced by 35 %. Hence, the total health-care cost of starting treatment with adjunctive SIS instead of standard care alone was estimated to reduce payer costs by 1% (i.e. $105 per patient) over 12 months following the start of treatment. Conclusion: Within the study's limitations, the use of adjunctive SIS instead of standard care alone improves outcome for less cost and thereby affords a cost-effective use of Medicare-funded resources in the management of neuropathic foot ulcers among adult patients with type 1 or 2 diabetes mellitus in the US. Declaration of interest: The authors certify that they have no affiliation with or financial involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in this manuscript, although CRW is an employee of the sponsor, Smith and Nephew, Inc. JLF, AG and CJA are speakers and/or clinical trial investigators in the field of diabetes, all of which are independent of this current study. Additionally, JLF and AG have provided consultancy/advisory services to Smith and Nephew Inc., and received research funding independently of this current study. The authors have no other conflicts of interest that are directly relevant to the content of this manuscript.

LanguageEnglish (US)
PagesS12-S24
JournalJournal of Wound Care
Volume26
DOIs
StatePublished - Jan 1 2017

Fingerprint

Diabetic Foot
Small Intestine
Cost-Benefit Analysis
Swine
Standard of Care
Ulcer
Medicare
Costs and Cost Analysis
Foot Ulcer
Conflict of Interest
Health Resources
Debridement
Consultants
Type 1 Diabetes Mellitus
Amputation
Health Care Costs
Type 2 Diabetes Mellitus
Lower Extremity
Therapeutics
Research Personnel

Keywords

  • Cost-effectiveness
  • Diabetic foot ulcer
  • Oasis Ultra
  • Porcine small intestine submucosa tri-layer matrix
  • United States

ASJC Scopus subject areas

  • Fundamentals and skills
  • Nursing (miscellaneous)

Cite this

Cost-effectiveness of using adjunctive porcine small intestine submucosa trilayer matrix compared with standard care in managing diabetic foot ulcers in the US. / Guest, J. F.; Weidlich, D.; Singh, H.; La Fontaine, J.; Garrett, A.; Abularrage, C. J.; Waycaster, C. R.

In: Journal of Wound Care, Vol. 26, 01.01.2017, p. S12-S24.

Research output: Contribution to journalArticle

@article{a2b1921411cc4ea3953a88264eaee2f6,
title = "Cost-effectiveness of using adjunctive porcine small intestine submucosa trilayer matrix compared with standard care in managing diabetic foot ulcers in the US",
abstract = "Objective: To estimate the cost-effectiveness of using tri-layer porcine small intestine submucosa (SIS; Oasis Ultra) as an adjunct to standard care compared with standard care alone in managing diabetic foot ulcers (DFUs) in the US, from the perspective of Medicare. Method: A Markov model was constructed to simulate the management of diabetic neuropathic lower extremity ulcers over a period of one year in the US. The model was used to estimate the costeffectiveness of initially using adjunctive SIS compared with standard care alone to treat a DFU in the US at 2016 prices. Results: At 12 months after the start of treatment, the use of adjunctive SIS instead of standard care alone is expected to lead to a 42 \{%} increase in the number of ulcer-free months, 32 \{%} increase in the probability of healing, a 3 \{%} decrease in the probability of developing complicated ulcers and a 1 \{%} decrease in the probability of undergoing an amputation. Health-care resource use is expected to be reduced by 11-14 \{%} among patients who are initially managed with adjunctive SIS compared with those initially managed with standard care alone, with the exception of debridement, which is expected to be reduced by 35 \{%}. Hence, the total health-care cost of starting treatment with adjunctive SIS instead of standard care alone was estimated to reduce payer costs by 1\{%} (i.e. $105 per patient) over 12 months following the start of treatment. Conclusion: Within the study\{textquoteleft}s limitations, the use of adjunctive SIS instead of standard care alone improves outcome for less cost and thereby affords a cost-effective use of Medicare-funded resources in the management of neuropathic foot ulcers among adult patients with type 1 or 2 diabetes mellitus in the US. Declaration of interest: The authors certify that they have no affiliation with or financial involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in this manuscript, although CRW is an employee of the sponsor, Smith and Nephew, Inc. JLF, AG and CJA are speakers and/or clinical trial investigators in the field of diabetes, all of which are independent of this current study. Additionally, JLF and AG have provided consultancy/advisory services to Smith and Nephew Inc., and received research funding independently of this current study. The authors have no other conflicts of interest that are directly relevant to the content of this manuscript.",
keywords = "Cost-effectiveness, Diabetic foot ulcer, Oasis Ultra, Porcine small intestine submucosa tri-layer matrix, United States",
author = "Guest, {J. F.} and D. Weidlich and H. Singh and {La Fontaine}, J. and A. Garrett and Abularrage, {C. J.} and Waycaster, {C. R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.12968/jowc.2017.26.Sup1.S12",
language = "English (US)",
volume = "26",
pages = "S12--S24",
journal = "Journal of wound care",
issn = "0969-0700",
publisher = "MA Healthcare Ltd",

}

TY - JOUR

T1 - Cost-effectiveness of using adjunctive porcine small intestine submucosa trilayer matrix compared with standard care in managing diabetic foot ulcers in the US

AU - Guest,J. F.

AU - Weidlich,D.

AU - Singh,H.

AU - La Fontaine,J.

AU - Garrett,A.

AU - Abularrage,C. J.

AU - Waycaster,C. R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To estimate the cost-effectiveness of using tri-layer porcine small intestine submucosa (SIS; Oasis Ultra) as an adjunct to standard care compared with standard care alone in managing diabetic foot ulcers (DFUs) in the US, from the perspective of Medicare. Method: A Markov model was constructed to simulate the management of diabetic neuropathic lower extremity ulcers over a period of one year in the US. The model was used to estimate the costeffectiveness of initially using adjunctive SIS compared with standard care alone to treat a DFU in the US at 2016 prices. Results: At 12 months after the start of treatment, the use of adjunctive SIS instead of standard care alone is expected to lead to a 42 % increase in the number of ulcer-free months, 32 % increase in the probability of healing, a 3 % decrease in the probability of developing complicated ulcers and a 1 % decrease in the probability of undergoing an amputation. Health-care resource use is expected to be reduced by 11-14 % among patients who are initially managed with adjunctive SIS compared with those initially managed with standard care alone, with the exception of debridement, which is expected to be reduced by 35 %. Hence, the total health-care cost of starting treatment with adjunctive SIS instead of standard care alone was estimated to reduce payer costs by 1% (i.e. $105 per patient) over 12 months following the start of treatment. Conclusion: Within the study's limitations, the use of adjunctive SIS instead of standard care alone improves outcome for less cost and thereby affords a cost-effective use of Medicare-funded resources in the management of neuropathic foot ulcers among adult patients with type 1 or 2 diabetes mellitus in the US. Declaration of interest: The authors certify that they have no affiliation with or financial involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in this manuscript, although CRW is an employee of the sponsor, Smith and Nephew, Inc. JLF, AG and CJA are speakers and/or clinical trial investigators in the field of diabetes, all of which are independent of this current study. Additionally, JLF and AG have provided consultancy/advisory services to Smith and Nephew Inc., and received research funding independently of this current study. The authors have no other conflicts of interest that are directly relevant to the content of this manuscript.

AB - Objective: To estimate the cost-effectiveness of using tri-layer porcine small intestine submucosa (SIS; Oasis Ultra) as an adjunct to standard care compared with standard care alone in managing diabetic foot ulcers (DFUs) in the US, from the perspective of Medicare. Method: A Markov model was constructed to simulate the management of diabetic neuropathic lower extremity ulcers over a period of one year in the US. The model was used to estimate the costeffectiveness of initially using adjunctive SIS compared with standard care alone to treat a DFU in the US at 2016 prices. Results: At 12 months after the start of treatment, the use of adjunctive SIS instead of standard care alone is expected to lead to a 42 % increase in the number of ulcer-free months, 32 % increase in the probability of healing, a 3 % decrease in the probability of developing complicated ulcers and a 1 % decrease in the probability of undergoing an amputation. Health-care resource use is expected to be reduced by 11-14 % among patients who are initially managed with adjunctive SIS compared with those initially managed with standard care alone, with the exception of debridement, which is expected to be reduced by 35 %. Hence, the total health-care cost of starting treatment with adjunctive SIS instead of standard care alone was estimated to reduce payer costs by 1% (i.e. $105 per patient) over 12 months following the start of treatment. Conclusion: Within the study's limitations, the use of adjunctive SIS instead of standard care alone improves outcome for less cost and thereby affords a cost-effective use of Medicare-funded resources in the management of neuropathic foot ulcers among adult patients with type 1 or 2 diabetes mellitus in the US. Declaration of interest: The authors certify that they have no affiliation with or financial involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in this manuscript, although CRW is an employee of the sponsor, Smith and Nephew, Inc. JLF, AG and CJA are speakers and/or clinical trial investigators in the field of diabetes, all of which are independent of this current study. Additionally, JLF and AG have provided consultancy/advisory services to Smith and Nephew Inc., and received research funding independently of this current study. The authors have no other conflicts of interest that are directly relevant to the content of this manuscript.

KW - Cost-effectiveness

KW - Diabetic foot ulcer

KW - Oasis Ultra

KW - Porcine small intestine submucosa tri-layer matrix

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85016196067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016196067&partnerID=8YFLogxK

U2 - 10.12968/jowc.2017.26.Sup1.S12

DO - 10.12968/jowc.2017.26.Sup1.S12

M3 - Article

VL - 26

SP - S12-S24

JO - Journal of wound care

T2 - Journal of wound care

JF - Journal of wound care

SN - 0969-0700

ER -